A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
J Dermatolog Treat
; 34(1): 2253943, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-37968922
ABSTRACT
Inherited epidermolysis bullosa is a heterogeneous group of hereditary skin diseases characterized by skin (mucosa) fragility, which leads to blistering. Junctional epidermolysis bullosa is associated with mutations in genes expressing proteins of the dermo-epidermal junction. Dupilumab, an antibody that directly targets interleukin (IL)-4 receptor alpha, may be an effective treatment for dystrophic epidermolysis bullosa. We describe a case of junctional epidermolysis bullosa that improved with dupilumab.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Epidermólise Bolhosa Distrófica
/
Epidermólise Bolhosa Juncional
/
Epidermólise Bolhosa
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article